My lab is expanding on the above findings in collaboration with clinicians at Memorial Sloan Kettering, with the aim of identifying patients who have developed tumors with metastasis-favoring mutations.

Our inter-disciplinary team is generating mouse models that accurately reflect the core genetic changes of human metastatic prostate cancer in order to develop novel therapies using small molecules or RNA-interference technology developed at Cold Spring Harbor. In addition, the analysis of such tumors across species allows us to filter the vast amount of human genomic tumor information for relevant changes.